The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development
In this paper I examine how the promissory value of genetics is constituted through processes of scale and scaling, focussing on the relationship between “rare” and “common” forms of disease. I highlight the bodies and spaces involved in the production of post-genomic knowledge and technologies of A...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | New Genetics and Society |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14636778.2019.1637718 |
| _version_ | 1797681224003616768 |
|---|---|
| author | Richard Milne |
| author_facet | Richard Milne |
| author_sort | Richard Milne |
| collection | DOAJ |
| description | In this paper I examine how the promissory value of genetics is constituted through processes of scale and scaling, focussing on the relationship between “rare” and “common” forms of disease. I highlight the bodies and spaces involved in the production of post-genomic knowledge and technologies of Alzheimer's disease and the development of new disease-modifying drugs. I focus on the example of the development of a monoclonal antibody therapy for Alzheimer's disease. I argue that the process of therapeutic innovation, from genetic studies and animal models to phase III clinical trials, reflects the persistent importance of a genetic imaginary and a mutually constitutive relationship between the rare and the common in in shaping visions of Alzheimer's disease medicine. Approaching this relationship as a question of scale, I suggest the importance of attending to how and where genomic knowledge is “scaled” or proves resistant to scaling. |
| first_indexed | 2024-03-11T23:42:11Z |
| format | Article |
| id | doaj.art-4915cb6d3da54e8d892e0d2d04ec79f4 |
| institution | Directory Open Access Journal |
| issn | 1463-6778 1469-9915 |
| language | English |
| last_indexed | 2024-03-11T23:42:11Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | New Genetics and Society |
| spelling | doaj.art-4915cb6d3da54e8d892e0d2d04ec79f42023-09-19T15:22:17ZengTaylor & Francis GroupNew Genetics and Society1463-67781469-99152020-01-0139110112610.1080/14636778.2019.16377181637718The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug developmentRichard Milne0Wellcome Genome Campus – Society and Ethics Research GroupIn this paper I examine how the promissory value of genetics is constituted through processes of scale and scaling, focussing on the relationship between “rare” and “common” forms of disease. I highlight the bodies and spaces involved in the production of post-genomic knowledge and technologies of Alzheimer's disease and the development of new disease-modifying drugs. I focus on the example of the development of a monoclonal antibody therapy for Alzheimer's disease. I argue that the process of therapeutic innovation, from genetic studies and animal models to phase III clinical trials, reflects the persistent importance of a genetic imaginary and a mutually constitutive relationship between the rare and the common in in shaping visions of Alzheimer's disease medicine. Approaching this relationship as a question of scale, I suggest the importance of attending to how and where genomic knowledge is “scaled” or proves resistant to scaling.http://dx.doi.org/10.1080/14636778.2019.1637718alzheimer’s diseasegeneticsdrugsscalemodels |
| spellingShingle | Richard Milne The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development New Genetics and Society alzheimer’s disease genetics drugs scale models |
| title | The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development |
| title_full | The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development |
| title_fullStr | The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development |
| title_full_unstemmed | The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development |
| title_short | The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development |
| title_sort | rare and the common scale and the genetic imaginary in alzheimer s disease drug development |
| topic | alzheimer’s disease genetics drugs scale models |
| url | http://dx.doi.org/10.1080/14636778.2019.1637718 |
| work_keys_str_mv | AT richardmilne therareandthecommonscaleandthegeneticimaginaryinalzheimersdiseasedrugdevelopment AT richardmilne rareandthecommonscaleandthegeneticimaginaryinalzheimersdiseasedrugdevelopment |